What’s the current market cap for Regencell Bioscience stock?

Regencell Bioscience (RGC) has a market cap of $6bn as of June 22, 2026.

What is the P/E ratio for Regencell Bioscience stock?

The price to earnings (P/E) ratio for Regencell Bioscience (RGC) stock is 0 as of June 22, 2026.

Does Regencell Bioscience stock pay dividends?

No, Regencell Bioscience (RGC) stock does not pay dividends to its shareholders as of June 22, 2026.

When is the next Regencell Bioscience dividend payment date?

Regencell Bioscience (RGC) stock does not pay dividends to its shareholders.

What is the beta indicator for Regencell Bioscience?

Regencell Bioscience (RGC) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Regencell Bioscience stock | $RGC Share Price

About Regencell Bioscience

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

Ticker

$RGC

Sector

Health

Primary listing

NASDAQ

Employees

10

Headquarters

Causeway Bay, Hong Kong

Website

www.regencellbioscience.com

RGC Metrics

BasicAdvanced

$6bn

-

-$0.01

1.64

-

Bulls say / Bears say

Regencell completed a registered direct offering of 985,222 ordinary shares at $20.30 per share, raising about $20 million in gross proceeds to support research and operations (Reuters via Investing.com).

Regencell filed a prospectus supplement on March 30, 2026, under its Form F-3 shelf registration, launching an at-the-market offering program to issue up to $500 million of ordinary shares, enabling flexible future funding for working capital and development (SEC Form 6-K).

A $19 million commitment from a new key institutional investor anchored the May 2026 direct offering, evidencing strong external confidence in Regencell’s pipeline of traditional Chinese medicine treatments for ADHD and ASD (Reuters via Investing.com).

Regencell’s net loss increased 187% year-over-year to $5.3 million for the six months ended December 31, 2025, due to a 170% rise in operating expenses, reflecting accelerated cash burn and growing administrative costs (SEC Form 6-K).

As of December 31, 2025, Regencell had just $2.4 million in cash and $3.0 million in total assets, versus a $5.3 million half-year loss, indicating less than six months of operational runway without new financing (SEC Form 6-K).

On April 24, 2026, a class action lawsuit was brought against Regencell alleging misleading statements regarding share volatility. An ongoing government investigation could result in fines, sanctions, or legal expenses (SEC Form 6-K).

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

RGC Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

RGC News

AllArticlesVideos

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Business Wire·7 hours ago

Relevant Gold Announces Results of Annual and Special General Meeting and Welcomes New Board Member

Accesswire·4 days ago

Relevant Gold South Pass VTEM Survey Defines Multi-Kilometre Structural Corridors with High Priority Drill Targets

Accesswire·5 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.